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hect@uic.edu (ChuAbstract The absorption proﬁles of Schisandra chinensis were evaluated using the human Caco-2 cell
monolayer and rat everted gut sac models, as well as in rat plasma. By analyzing the chromatographic
and MSn characteristics of individual peak acquired by HPLC-DAD-APCI-MSn determination,
thirteen lignans were identiﬁed as the major in vitro absorbable components of the Schisandra extract.
Most of these compounds were also detected and identiﬁed in rat plasma after an oral administration
of the Schisandra extract, except for angeloyl(tigloyl)gomisin H and angeloyl(tigloyl)gomisin Q, whose
structures possess an ester group at the cyclooctadiene ring. In addition, four metabolites,
corresponding to the hydroxylation and demethylation products of schisandrin and the hydrolysis
derivative of angeloyl(tigloyl)gomisin Q, were tentatively identiﬁed. The results demonstrate that
Schisandra lignans are the major absorbable components of this crude drug, and hydroxylation,
demethylation and hydrolysis are important metabolic transformations of the absorbable lignans.
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HPLC-MS analysis of Schisandra lignans and their metabolites 471. Introduction
The fruit of Schisandra chinensis (Turcz.) Baill., known in
Chinese medicine as Wu-Wei-Zi, is widely used for the
treatment of excessive loss of essential energy and body ﬂuid.
This crude drug is ofﬁcially recorded in the Chinese Pharma-
copoeia as a tonic, sedative and astringent agent1. In the
health-food market, products containing S. chinensis are often
claimed to possess antioxidant, neuro-protective, or liver-
protective properties2–5. Chemically, a family of dibenzocy-
clooctadiene lignans has been found in this plant drug and
many of them have shown biological activities6. The pharma-
cokinetics of some of the Schisandra lignans, such as schisan-
drin and g-schisandrin, has been studied using experimental
animals7–10. There are also reports on the intestinal absorption
of active ingredients of S. chinensis extracts10–13. However,
most previous studies focused on one or several lignans, and
information on the absorption proﬁle of the lignans remains to
be established, despite the crude extract of this herb is often
used in traditional medicine.
Liquid chromatography coupled with mass spectrometry
(LC-MS) is a useful tool for rapid identiﬁcation of chemicals
in herbal extracts and in biological specimens. The high
sensitivity and selectivity of MS facilitate the detection of
minor constituents in complex mixtures. The chromatographic
characters and mass spectrometric fragmentation behaviors of
Schisandra lignans have been investigated in recent years14–18.
The human Caco-2 intestinal epithelial cell monolayer
model and rat everted gut sac have been used as in vitro
models for studying the intestinal absorption of drugs19,20.
In this study, the absorption of S. chinensis was evaluated in
both models, and HPLC-DAD-APCI-MS was employed for
the identiﬁcation of absorbable compounds. In addition, the
absorbable components and related metabolites were further
determined in rat plasma after oral administration of the
Schisandra extracts.2. Materials and methods
2.1. Chemicals and reagents
Schisandrin, schisantherin A, schisandrin A and schisandrin B
(purity 498%) were purchased from the National Institute
for the Control of Pharmaceutical and Biological Products
(Beijing, China). Schisandrol B was obtained from the Hong
Kong Jockey Club Institute of Chinese Medicine with purity
497%; gomisin D, angeloylgomisin F and gomisin G (purity
495%) were gifts from Dr. Yan Zhou of the same institution.
Dried berries of S. chinensis were obtained from Zhixin
Pharmaceutical Co., Ltd. (Guangzhou, China) and authenti-
cated by Ms. Yu-Ying Zong of our School. Voucher speci-
mens have been deposited in the School of Chinese Medicine,
the Chinese University of Hong Kong. Acetonitrile and
triﬂuoroacetic acid (HPLC grade; Fisher, USA) were used
for chromatography; water was puriﬁed by a Milli-Q academic
puriﬁcation system (Millipore, USA).
The Caco-2 cells were purchased from the American Type
Culture Collection (ATCC, USA). Medium 199 powder (Gibco;
with Earle’s salts and L-glutamine, without NaHCO3), Dulbec-
co’s modiﬁed Eagle’s medium (DMEM), fetal bovine serum
(FBS), non-essential amino acid, antibiotics, Trypsin-EDTA(1 mmol/L) and Hank’s buffer salt solution (HBSS) were all
obtained from Invitrogen (USA). Dimethylsulfoxide (DMSO)
and N-2-hydroxyethylpiperazine-N0-2-ethanesulfonic acid
(HEPES) were purchased from Sigma (USA). All other chemi-
cals used were of analytical grade for laboratory use.
2.2. Preparation of Schisandra extracts
Dried fruits of S. chinensis (500 g) were soaked in distilled
water (4 L) for 30 min at room temperature, followed by
boiling for an hour. The extraction procedure was repeated
twice with fresh supplies of distilled water. The combined
aqueous solution was ﬁltered, concentrated under reduced
pressure and freeze-dried to afford an aqueous extract (35.2%
yield w/w based on dried herbs). Ethanol extract was obtained
by 70% ethanol extraction following the procedures described
above and the extract yield was 30.4%. The dry powder was
stored in a desiccator at room temperature until use.
2.3. Animals
Male Sprague-Dawley rats (250–280 g) were bred and housed
by the Laboratory Animal Services Centre of the Chinese
University of Hong Kong. All experiments were approved by
the Animal Research Ethics Committee, The Chinese Uni-
versity of Hong Kong. The animals were kept in a temperature
controlled room (2372 1C) with a 12-h light–dark cycle, with
free access to food and water. In the animal study, six rats
were orally given by gavage a single dose of Schisandra
aqueous extract (2 g/kg) or 70% ethanol extract (4 g/kg),
which was suspended in 0.5% sodium carboxymethyl cellu-
lose. Blood samples (0.3 mL) were collected by orbital bleed-
ing via heparinized capillary tubes under anesthetizing with
isoﬂurane at 0, 0.5, 1, 2, 4, 8 h. Plasma (0.15 mL) was obtained
by centrifugation at 7000 g for 10 min at room temperature
and frozen at 20 1C prior to analysis.
2.4. Caco-2 cell monolayer model experiments
Caco-2 cells were cultured in DMEM supplemented with 10%
FBS, 1% non-essential amino acid and penicillin and strepto-
mycin at 37 1C in humidiﬁed air containing 5% CO2. The cells
were seeded in collagen-coated Transwell inserts at a density
of 3 105 cells/well and cultured for 21 days prior to the
transport experiments. The medium (1.5 mL in the apical side
and 2.6 mL in the basolateral side) was changed every other
day. The integrity of cell monolayer was monitored by
measurement of transepithelial electrical resistance (TEER)
before and after transport study using the Millicell-ERS
system (Millipore Corp.); those showing TEER values below
800 O cm2 were not further used. In the transport study, the
monolayers were washed with HBSS containing 10 mmol/L
HEPES (pH 7.4), followed by pre-incubation for 25 min at
37 1C. After removal of the solutions, fresh transferred buffer
(1.5 mL) with or without Schisandra extract (2 mg/mL) was
added to the apical chamber and incubated at 37 1C. Aliquots
(500 mL) were taken from the basolateral chamber at 60, 120,
180 min and replaced with equal volume of transferred buffer
after each sampling. At the end of transport study, samples of
both sides were collected for analysis. All samples were stored
at 20 1C until analysis.
Figure 1 HPLC-DAD chromatograms of (a) a pure standard
mixture of schisandrin, schisandrol B, schisandrin A and schisan-
drin B, (b) aqueous extract and (c) 70% ethanol extract of
Schisandra chinensis fruits. The detection wavelength was set at
230 nm.
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Six adult male Sprague-Dawley rats were fasted overnight,
sacriﬁced by cervical dislocation, and the small intestine was
excised and ﬂushed with normal saline at room temperature. The
intestine was then immediately placed in TC 199 solution
maintained at 37 1C and oxygenated (O2/CO2, 95%:5%). With
the aid of a smooth glass rod, the intestine was everted gently and
sealed with silk braided sutures in one end before the gac sac was
ﬁlled with fresh TC 199 medium. After sealing the other end, the
small gut sac (3–4 cm in length) was placed in a 50 mL
Erlenmeyer ﬂask containing 10 mL medium with or without S.
chinensis aqueous extract (10 mg/mL), maintained under a ﬂow of
95% O2. The sacs were incubated at 37 1C in an oscillating water
bath (50 cycles/min) for 90 min. The sacs were taken out, washed
with saline and blotted dry. After cutting open the sac, the serosal
and mucosal solutions were harvested for analysis. All samples
were stored at 20 1C in a freezer until HPLC-MS analysis.
2.6. Sample processing and HPLC-MS conditions
All specimens were allowed to thaw at room temperature.
The samples obtained from Caco-2 cell model and rat everted
gut sac were subjected to ﬁltration through 0.45 mmol/L
membrane before HPLC-MS analysis. The rat plasma
(100 mL) was extracted with 150 mL acetonitrile, and the
supernatant after centrifugation was collected for HPLC-MS
analysis. All samples were separated on a Prevail C18 column
(250 mm 4.6 mm I.D., 5 mm, Alltech) by an Agilent 1100
HPLC system (Agilent Technologies, CA, USA). The ﬂow
rate was 0.8 mL/min. The mobile phase consisted of 0.1%
triﬂuoroacetic acid water (A) and acetonitrile (B) with a
gradient elution of 20% B at 0–5 min; 20–45% B at
6–35 min; 45–60% at 35–50 min; 60–100% B at 50–60 min.
The column temperature was maintained at 25 1C. The
injection volume was 60 mL and the detection wavelengths
were set at 210, 230, 254 and 280 nm. The efﬂuent was directly
introduced to the APCI-MS (Agilent 1100 series LC/MSD
Trap SL system, USA) for analysis. The APCI-MS analysis
was divided into two time segments. The ﬁrst 4 min were set as
waste to avoid the inﬂux of inorganic ions into the mass
analyzer; subsequent analysis was carried out under the
following optimized conditions: positive ion mode; nebulizer
(N2), 60 psi; dry gas (N2), 5 L/min; drying gas temperature,
325 1C; target mass, 500 m/z; trap drive level, 80%, full scan
range, 140–1100 m/z. Two precursor ions were selected for
MSn (n¼2–3) experiments in automatic mode with active
exclusion. The fragmentation amplitude was 1.20 V.
3. Results
3.1. Quantiﬁcation of major lignans in Schisandra extracts
The four major lignans, schisandrin, schisandrol B, schisan-
drin A and schisandrin B, were well separated (Fig. 1).
Simultaneous quantiﬁcation of these compounds was per-
formed using UV detection at 230 nm. The calibration curves
showed good linear correlation (r2Z0.9995) between peak
area and concentration at the range from 0.5 to 200 mg/mL.
Intra- and inter-day precision of the method was within the
acceptable limits of R.S.D.o5%. Samples were stable within72 h at room temperature (R.S.D.o3%). The recovery of each
analyte was within the range of 96.5–108.9%. Schisandrin was
found to be the most abundant lignan, constituting 75.4%
(2.96 mg/g) and 46.2% (15.48 mg/g) of total lignans in the
aqueous extract and 70% ethanol extract, respectively. The
contents of schisandrol B, schisandrin A and schisandrin B in
the aqueous extract were 852, 49 and 60 mg/g, respectively,
while those in 70% ethanol extract increased to 7.20, 2.31 and
8.53 mg/g, respectively.3.2. HPLC-MSn analysis of lignan reference compounds
In order to achieve more information for the identiﬁcation of
absorbable components of S. chinensis, a lignan standard mixture,
containing schisandrin, gomisin D, schisandrol B, angeloylgomi-
sin F, gomisin G and schisantherin A, was separated under the
above HPLC condition, and subsequently introduced to APCI
source for characterizing their MS behaviors and dissociation
patterns. The chemical structures and MS spectra of the six
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Figure 2 Chemical structures of Schisandra lignans characterized in this study.
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respectively. The ion patterns in ﬁrst-stage spectra exhibited
notable difference from those reported in ESI-MS analysis18,21.
In our study, the protonated molecular ion [MþH]þ was much
less intensive and the adduct ions [MþNa]þ or [MþK]þ were
hardly observed. Alternatively, if the lignan possesses an ester
group in its chemical structure, such as gomisin D and schi-
santherin A, it likely formed an adduct ion [MþNH4]þ as the
base peak; if an –OH substitution group is present in the C-7
position, such as schisandrin and schisandrol B, the fragment ion
[MþHH2O]þ produced from the loss of H2O would be the base
peak. In addition, the presence of an ester group in the chemical
structure also facilitates the formation of fragment ions by loss of
a molecule of organic acid in the ﬁrst-stage spectra, indicating the
involvement of in-source collision-induced dissociation (CID).
For the lignans showing identical MS spectra, such as gomisin G
and schisantherin A, it was feasible to differentiate these isomers
by further MSn (n¼2–3) analysis.
Two most abundant ions in the ﬁrst-stage spectra were selected
as the precursor ions for CID fragmentation to produce MS/MS
product ions. The most prominent resulting product ions werethen selected for further MS3 fragmentation. Based on the product
ions observed in the multi-stage spectra, the characteristic dis-
sociation rules of the lignans showed good agreement with the
previous reports18,21 as summarized below. Firstly, the loss of
neutral molecules of –CH3, H2O and –OCH3 dominates in the
multi-stage fragmentations, resulting in the formation of
[MþH15]þ, [MþH18]þ and [MþH31]þ ions, respectively.
The loss of CH2O is also a dominant elimination when a
methylenedioxy group is attached to the benzoic ring, such as
schisandrol B and schisantherin A. Secondly, the presence of an –
OH group at the C-7 position leads to the easy loss of H2O, which
could maintain the stability of the chemical structure. Thirdly, the
presence of an ester group (e.g. schisantherin A and angeloylgo-
misin F) leads to the elimination of a molecule of organic acid,
such as benzoic acid (Dm¼122u) and 2-methyl-2-butenoic acid
(Dm¼100u), prior to further fragmentation. Fourthly, different
substitution sites of the methylenedioxy group could lead to the
formation of diagnostic product ions that enable us to distinguish
the isomers with identical ﬁrst-stage spectra. For example,
schisantherin A (C12-13 position substituted) and gomisin G
(C2-3 position substituted) produce the same fragment ions at m/z
Figure 3 MS spectra of six lignan standards: (a) schisandrin; (b) gomisin D; (c) schisandrol B; (d) angeloylgomisin F; (e) gomisin G and
(f) schisantherin A.
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ions at m/z 385 and 383 for schisantherin A and gomisin G,
respectively. The chromatographic and mass spectrometric char-
acteristics of the lignan standards are summarized in Table 1.3.3. In vitro absorbable components of S. chinensis extract
Rat everted gut sac and Caco-2 cell monolayer system are
universal in vitro models to study drug transport. The absorption
process in our body can be mimicked by the transport from
mucosal solution to serosal solution in the gut sac, or from the
apical side to basolateral side across Caco-2 cell monolayer. In
this study, the aqueous extract of S. chinensis exhibited similar
absorption proﬁles in these two in vitro models. Fig. 4 shows the
LC-MS base peak chromatograms of the samples obtained from
the Caco-2 cell monolayer model. Thirteen peaks (P1–P13) were
characterized in the basolateral solution. The identities of thesecompounds were established by comparing the retention time
and APCI-MSn data with those of reference compounds or with
the data reported in the literature (Table 1). They are, namely,
schisandrin (P1), gomisin D (P2), schisandrol B (P3), angeloylgo-
misin H (P4 or P5), tigloylgomisin H (P4 or P5), angeloylgomisin
Q (P6 or P7), tigloylgomisin Q (P6 or P7), tigloylgomisin F (P8),
angeloylgomisin F (P9), gomisin G (P10), schisantherin B (P11 or
P12), schisantherin C (P11 or P12) and schisantherin A (P13).
3.4. Absorbable and metabolic components of S. chinensis
extract in rat plasma
The absorption proﬁle of S. chinensis was also determined in rat
plasma after oral administration of Schisandra aqueous extract
and 70% ethanol extract. The HPLC-MSn method was again
employed to analyze the absorbable components and related
metabolites. The HPLC-MS chromatograms (Fig. 5) show that
the signals of absorbable lignans in the aqueous extract group
Table 1 LC-MSn characterization and molecular weight (MW) of the lignan standards (STD), absorbable compounds and
related metabolites in the Caco-2 cell monolayer, rat everted gut sac models and in rat plasma.
Code tR
(min)
MSn (m/z) and relative abundance (%) MW Identiﬁcation
P1/STD1 13.2 MS: 433(11), 415(100) 432 Schisandrin
MS2 [433]: 415(100)
MS2 [415]: 400(28), 384(100), 373(12), 359(18.4)
MS3 [384]: 369(100), 353(38), 338(23), 322(10)
P2/STD2 16.1 MS: 548(100), 531(34) 530 Gomisin D
MS2 [548]: 531(100), 485(72), 401(84), 383(4)
MS2 [531]: 485(38), 401(100), 383(29), 371(6), 353(6)
MS3 [401]: 383(100), 371(7), 353(14), 341(80)
P3/STD3 18.5 MS: 399(100) 416 Schisandrol B
MS2 [399]: 384(13), 369(100), 368(60), 357(14), 343(14),
337(42)
MS3 [368]: 353(84), 337(100), 323(10)
P4 19.9 MS: 501(15), 483(100), 401(6) 500 Angeloylgomisin
MS2 [501]: 483(100), 401(55) H/tigloylgomisin H
MS2 [483]: 451(72), 436(10), 427(21), 409(15), 401(100),
399(50), 395(21), 369(65)
MS3 [401]: 386(16), 370(52), 369(100), 359(17), 337(21)
P5 23.0 MS: 501(5), 483(100), 401(6) 500 Angeloylgomisin
MS2 [501]: 483(100), 401(55) H/tigloylgomisin H
MS2 [483]: 451(52), 436(8), 427(15), 409(12), 401(100),
399(43), 395(19), 369(44)
MS3 [401]: 386(10), 370(68), 369(100), 359(17), 337(25)
P6 22.0 MS: 548(100), 431(43) 530 Angeloylgomisin
MS2 [548]: 431(100) Q/tigloylgomisin Q
MS2 [431]: 413(10), 399(36), 389(30), 387(100), 372(30),
356(39)
MS3 [387]: 372(17), 356(100)
P7 25.3 MS: 548(100), 431(45) 530 Angeloylgomisin
MS2 [548]: 431(100) Q /tigloylgomisin Q
MS2 [431]: 413(12), 399(39), 389(35), 387(100), 372(34),
356(43)
MS3 [387]: 372(21), 356(100)
P8 27.7 MS: 532(100), 415(30) 514 Tigloylgomisin F
MS2 [532]: 415(100)
MS2 [415]: 397(31), 383(73), 373(78), 371(100), 356(49),
341(91), 340(44)
MS3 [371]: 341(100), 340(82)
P9/STD4 31.4 MS: 532(100), 415(32) 514 Angeloylgomisin F
MS2 [532]: 415(100)
MS2 [415]: 397(33), 383(74), 373(80), 371(100), 356(51),
341(90), 340(38)
MS3 [371]: 341(100), 340(80)
P10/STD5 32.5 MS: 554(100), 415(23) 536 Gomisin G
MS2 [554]: 415(100)
MS2 [415]: 397(17), 383(57), 373(54), 371(100), 356(51),
341(81), 340(26)
MS3 [371]: 341(100), 340(59)
P11 34.1 MS: 532(100), 415(26) 514 Schisantherin
MS2 [532]: 415(100) B/Schisantherin C
MS2 [415]: 397(4), 385(22), 373(18), 371(100), 341(10),
340(14)
MS3 [371]: 356(19), 341(41), 340(100)
P12 37.2 MS: 532(100), 415(27) 514 Schisantherin B/
MS2 [532]: 415(100) Schisantherin C
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Table 1 (continued )
Code tR
(min)
MSn (m/z) and relative abundance (%) MW Identiﬁcation
MS2 [415]: 397(6), 385(32), 373(25), 371(100), 341(10),
340(16)
MS3 [371]: 356(25), 341(50), 340(100)
P13/STD6 37.8 MS: 554(100), 415(17) 536 Schisantherin A
MS2 [554]: 415(100)
MS2 [415]: 397(12), 385(71), 373(45), 371(100), 341(39),
340(36)
MS3 [371]: 356(17), 341(69), 340(100)
P14 41.3 MS: 515(100) 514 Gomisin E
MS2 [515]: 469(22), 385(100), 355(30), 343(3), 323(10)
MS3 [385]: 367(5), 355(100), 353(16), 343(13), 323(30)
P15 45.1 MS: 417(100) 416 Schisandrin A
MS2 [417]: 402(36), 386(8), 370(8), 347(53), 332(10),
316(100)
MS3 [316]: 301(100), 285(50)
P16 48.9 MS: 401(100), 418(20) 400 Schisandrin B
MS2 [401]: 386(60), 371(60), 331(80), 300(100)
MS3 [300]: 285(100), 270(30), 258(15), 242(20), 227(15)
M1 5.5 MS: 435(20), 417(100) 434 Demethylated,
MS2 [435]: 417(100) hydroxylated-schisandrin
MS2 [417]: 385(30), 359(100), 327(40)
MS3 [359]: 344(20), 327(100), 297(35)
M2 7.2 MS: 449(10), 431(100) 448 Hydroxylated-
MS2 [449]: 431(100) schisandrin
MS2 [431]: 401(10), 373(100), 358(10), 342(20)
MS3 [373]: 358(20), 342(100):
M3 8.1 MS: 401(100) 418 Demethylated-
MS2 [401]: 386(15), 370(100), 338(80) schisandrin
MS3 [370]: 355(45), 338(100), 324(80), 314(40)
M4 8.6 MS: 431(100), 401(35) 430 Hydrolyzed-angeloyl
MS2 [431]: 413(20), 399(60), 387(100), 372(40), 356(30) (tigloyl)gomisin Q
MS3 [387]: 372(100), 356(45), 347(25), 330(30), 313(25)
Jia-ming Yang et al.52were less intensive than those in ethanol extract group. Such a
phenomenon could be explained by the lower contents of lignan
compounds present in the aqueous extract. Analysis of the
chromatographic and MSn data led to the identiﬁcation of
schisandrin (P1), gomisin D (P2), schisandrol B (P3), angeloyl-
gomisin H/tigloylgomisin H (P5), schisantherin B/schisantherin
C (P11, P12) and schisantherin A (P13) in both groups. In
addition, angeloylgomisin H/tigloylgomisin H (P4), gomisin G
(P10), gomisin E (P14), schisandrin A (P15) and schisandrin B
(P16) were identiﬁed in the plasma of rats treated with an
ethanol extract. Interestingly, angeloylgomisin Q (P6 or P7),
tigloylgomisin Q (P6 or P7), tigloylgomisin F (P8) and
angeloylgomisin F (P9), which were present in the in vitro
absorption proﬁles, were not detected in the plasma.
In addition to the absorbed lignans, four new peaks (M1–M4)
were detected between retention times of 5 and 10 min (Fig. 5).
As reported in previous studies, hydroxylation and demethyla-
tion are the dominant forms of ﬁrst-phase metabolism of
Schisandra lignans7,22. M1–M3 showed MS dissociation patterns
similar to that of schisandrin, and the mass differences between
M1–M3 and schisandrin were 2u, 16u and 14u, respectively.Thus, M1–M3 were tentatively identiﬁed to be the demethylated/
hydroxylated-, hydroxylated- and demethylated-derivatives of
schisandrin, respectively. On the other hand, the MSn spectra
of M4 demonstrated that the mass difference between M4 and
angeloyl(tigloyl)gomisin Q were 100u, suggesting the loss of 2-
methyl-2-butenoic acid. Moreover, the characteristic fragment
ions of M4 were identical with those yielded from the product
ion (m/z 415) of angeloyl(tigloyl)gomisin Q. Therefore, M4 was
tentatively identiﬁed to be a hydrolyzed-angeloyl(tigloyl)gomisin
Q. Table 2 shows the distribution of lignan structures in the
in vitro and in vivo models.
4. Discussion
The fruit of S. chinensis is among the most commonly used herbs
in Traditional Chinese Medicine. The present study improves the
knowledge on the pharmacokinetics of S. chinensis supplementary
to the previous studies on the pure forms of Schisandra
lignans9–11,13. The identiﬁed absorbable components suggested
the presence of multiple active ingredients in S. chinensis and (or)
the multi-target of pharmacological actions of this herb. The
Figure 5 HPLC-MS chromatograms of rat plasma obtained at 2 h after oral administration with Schisandra extracts. (a) Extracted ion
chromatogram (EIC) for samples treated with an aqueous extract (4 g/kg) and (b) base peak chromatogram (BPC) for samples treated
with 70% ethanol extract (2 g/kg).
Figure 4 Representative LC-MS basic peak chromatograms (BPC) in positive mode of samples obtained from the Caco-2 cell monolayer
model after 180 min incubation. (a) Blank basolateral solution, (b) basolateral solution and (c) apical solution from samples incubated
with Hank’s buffer solution containing the aqueous extract of S. chinensis (2 mg/mL).
HPLC-MS analysis of Schisandra lignans and their metabolites 53similar absorption proﬁles in rat everted gut sac and Caco-2 cell
monolayer models indicated that these components are likely
absorbable in both rat and human subjects. Our further quanti-
tative study also demonstrated that the apparent permeability
of schisandrin across Caco-2 cell monolayer was over 14 106
cm/s, suggesting a high intestinal absorption potential of this
compound23.In rat plasma obtained after oral administration of Schisan-
dra extracts, most of the absorbable lignans in vitro were again
identiﬁed except for the compounds whose structures possess an
ester group. It is plausible that the ester group (angeloyl or
tigloyl substitution) attached on the cyclooctadiene ring is
rapidly metabolized by the hydrolase in the intestinal wall,
enteric bacteria or liver. This speculation was further supported
Table 2 Absorbable compounds and related metabolites of Schisandra chinensis characterized in the Caco-2 cell monolayer, rat
everted gut sac in vitro models and in rat plasma.
Code Compound Aqueous extract Ethanol extract
Rat everted
gut sac
Caco-2 cell
monolayer
Rat
plasma
Rat
plasma
P1 Schisandrin O O O O
P2 Gomisin D O O O O
P3 Schisandrol B O O O O
P4 Angeloylgomisin H/tigloylgomisin H O O O
P5 Angeloylgomisin H/tigloylgomisin H O O O O
P6 Angeloylgomisin Q/tigloylgomisin Q O O
P7 Angeloylgomisin Q/tigloylgomisin Q O O
P8 Tigloylgomisin F O O
P9 Angeloylgomisin F O O
P10 Gomisin G O O O
P11 Schisantherin B/schisantherin C O O O O
P12 Schisantherin B/schisantherin C O O O O
P13 Schisantherin A O O O O
P14 Gomisin E O
P15 Schisanrin A O
P16 Schisandrin B O
M1 Demethylated, hydroxylated-schisandrin O O
M2 Hydroxylated-schisandrin O O
M3 Demethylated-schisandrin O O
M4 Hydrolyzed-angeloyl(tigloyl)gomisin Q O O
Jia-ming Yang et al.54by the identiﬁcation of metabolite yielded from the hydrolysis of
angeloyl(tigloyl)gomisin Q. Moreover, the demethylated/hydro-
xylated-, hydroxylated- and demethylated-derivatives of schisan-
drin were also detected in rat plasma that was in agreement with
the previous reports on the metabolism of Schisandra lignans7,22.
The present results thus provide further information on the
absorption and metabolic characteristics of S. chinensis in
addition to the previous study that only determined the lignan
components in rat plasma21. The differences between in vitro
and in vivo results in this study indicated that rapid metabolic
transformation, such as hydrolysis, hydroxylation and demethy-
lation, should be taken into account in the pharmacological
studies of Schisandra lignans, as undesirable metabolism may
reduce the bioavailability of the parent compounds.
According to the absorption proﬁles in rat plasma acquired
by HPLC-MS (Fig. 5), the signals of the identiﬁed lignan
compounds (in particular schisandrin) in aqueous extract
were considerably less intensive than those in ethanol extract.
A previous report compared the oral pharmacokinetics of
schisandrin in the forms of monomer and Schisandra extract,
and revealed that the AUC and half-life values of schisandrin in
the extract were increased as compared to monomer, but the
underlined mechanism was not investigated. Considering several
Schisandra lignans, such as schisandrin A and schisandrin B,
have been identiﬁed as cytochrome P450 (CYP) enzymes
inhibitors24, these concomitantly absorbed lignans may increase
the bioavailability of schisandrin through CYP enzyme inhibi-
tion, which could also interpret the absorption difference
between aqueous extract and ethanol extract in our study.
Nevertheless, the observation needs to be clariﬁed by further
investigations.
In summary, the present study investigated the absorption
and metabolism of S. chinensis in the rat everted gut sac andhuman Caco-2 cell monolayer models, and in rat plasma with
the aid of HPLC-APCI-MSn analysis. By analyzing the chro-
matographic and MSn characteristics, thirteen Schisandra lig-
nans were identiﬁed in the in vitro absorption proﬁles of
Schisandra aqueous extract. These components of S. chinensis
are most likely orally absorbable in both rat and human
subjects. Most of the lignan compounds were also detected in
the rat plasma after oral administration except for four lignans,
whose chemical structures possess an ester group (angeloyl or
tigloyl substitution) on the cyclooctadiene ring. In addition, four
metabolites, corresponding to the hydroxylation and demethyla-
tion products of schisandrin and the hydrolysis derivative of
angeloyl(tigloyl)gomisin Q, were identiﬁed. The present results
provide useful information for further pharmacological and
pharmacokinetic of S. chinensis. This study also demonstrates
the successful combination of in vitromodels, animal system and
HPLC-MSn analysis in the analysis of absorption and metabolic
proﬁles of complex herbal extract.Acknowledgment
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